Does absorbed dose predict outcome in radionuclide therapy? · revision history

Revision 2

Accepted · core change · record

Changes against revision 1:

Title · changed
Revision 1: Does absorbed dose predict outcome in radionuclide therapy
Revision 2: Does absorbed dose predict outcome in radionuclide therapy?
Plain
In external beam treatment, more dose means more tumour control. Whether the same holds for radioactive drugs, where dose arrives slowly and unevenly, has not been shown convincingly.
Precise · changed · core
Revision 1: Establish whether tumour absorbed dose, computed from quantitative imaging and time-activity integration for Lu-177 labelled agents, predicts response with a slope distinguishable from zero, and whether kidney and marrow absorbed dose predicts toxicity. Typical delivered tumour doses span $10^3$ to $3 x 10^4\,\mathrm{rad}$ at dose rates of 1 to 100 rad/h. An answer is a dose-response relation with confidence intervals, or a demonstration that dose rate and biological factors dominate.
Revision 2: Establish whether tumour absorbed dose, computed from quantitative imaging and time-activity integration for Lu-177 labelled agents, predicts response with a slope distinguishable from zero, and whether kidney and marrow absorbed dose predicts toxicity. Typical delivered tumour doses span $10^3$ to $3 \times 10^4\,\mathrm{rad}$ at dose rates of 1 to 100 rad/h. An answer is a dose-response relation with confidence intervals, or a demonstration that dose rate and biological factors dominate.
Settled by
Prospective trials randomizing or stratifying by measured absorbed dose rather than administered activity.
Kind
well-posed
Answer type
yes-no
References
(empty)
Literature status
partially-resolved
Status note
Dosimetry-guided dose escalation studies reported through 2024 support a relation for some agents; fixed-activity dosing remains standard practice.
Posed since
2000

Decisions